Table 1

Serum CK levels and thymoma-associated autoantibody levels in patients with thymoma before and after avelumab treatment

PatientSerum CK (IU/L)Anti-AChR (nmol/L)Anti-STR (dilutions)Anti-VGKC (nmol/L)Anti-GAD65 (nmol/L)Anti-α3 (nmol/L)Anti-CRMP5Anti-AMPARAnti-GABABRAnti-NMDAAnti-LGI1Anti-Caspr2
#1 Pre552.5938400NT0NegNegNegNegNegNeg
#1 Day 15 post17922.36192000.020NegNegNegNegNegNeg
#2 Pre860.21Neg000NegNegNegNegNegNeg
#2 Day 43 post10460.24Neg000NegNegNegNegNegNeg
#3 Pre1300.367680000NegNegNegNegNegNeg
#3 Day 15 post39390.317680000NegNegNegNegNegNeg
#4 Pre770Neg000NegNegNegNegNegNeg
#4 Day 15 post600Neg000NegNegNegNegNegNeg
#5 Pre4350Neg0.1100NegNegNegNegNegNeg
#5 Day 15 post4730Neg0.1500NegNegNegNegNegNeg
#6 Pre910.7330 7200.0600NegNegNegNegPosNeg
#6 Day 8 post7620.6761 4400.0100NegNegNegNegPosNeg
#7 Pre870Neg000NegNegNegNegNegNeg
#7 Day 15740Neg000NegNegNegNegNegNeg
#8 Pre450Neg000NegNegNegNegNegNeg
#8 Day 15280Neg000NegNegNegNegNegNeg
  • Note that serum CK levels included in this table are those obtained at the time sera were collected for autoantibody testing and may not reflect peak CK levels for a given patient. Autoantibody testing was performed at the Neuroimmunology Laboratory, Mayo Clinic, Rochester, Minnesota.

  • α3, ganglionic α3 acetylcholine receptor; AChR, acetylcholine receptor; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; Caspr2, contactin-associated protein-like 2; CK, creatine kinase; CRMP5, collapsin response-mediator protein-5; GABAR, gamma-aminobutyric acid receptor; GAD65, glutamic acid decarboxylase 65; LGI1, leucine-rich glioma-inactivated 1; Neg, negative; NMDA, N-methyl-D-aspartate receptor; NT, not tested; Pos, positive; STR, striational; VGKC, voltage -gated potassium channel.